Mike, (Mostly off-topic)
I think it is a good idea to diversify in the biotechs...If the sector heats up (and it is now, finally) then your portfolio profits, and if you hit on just 1 or 2 of your picks, then the sky is the limit. I was looking at Repligen 7 years ago, any you may be right that it is a worthwhile investment now...
I'm happy with Magainin. I think we've turned the corner (although the last time I said this, there was a wall around the corner). I think that Magn has more credibility than most of the others, but RGEN does have some good people. The same is true of Regeneron, although this has disappointed until now but has stron teaming.
I'm hoping to see BTGC make a dramatic move over the next few months. Got in on Techniclone under 1 (averaging at 1.5), ICN - with Hep-C drug looking good, rest of my portfolio in biotechs ok. PARS is also looking very good with 2 approvals and good pipeline (and around 3 right now).
Magainin has been investing in the asthma drug search - I think that is a good issue for the stockholders meeting. It's good to diversify, but looks like this may be way down the line before it pays off.
Good Luck,
Shep |
